TABLE 3.
Baseline characteristics according to fibrosis progression at follow-up
| No progression (n=60) | Significant fibrosis progression (n=22) | p | |
|---|---|---|---|
| Age (y) | 47.6 (±11.0) | 46.5 (±11.9) | 0.70 |
| Sex (% male) | 70.7 (n=42) | 77.3 (n=17) | 0.59 |
| BMI (kg/m2) | 28.0 (±4.1) | 28.4 (±3.2) | 0.66 |
| Diagnosis of T2DM (%) | 10.0 (n=6) | 18.2 (n=4) | 0.45 |
| Hypertension (%) | 70.6 (n=36) | 88.9 (n=16) | 0.20 |
| ALT (U/L) | 80.4 (±48.0) | 92.4 (±54.0) | 0.31 |
| AST (U/L) | 44.4 (±24.0) | 49.2 (±24.0) | 0.40 |
| AST/ALT ratio | 0.6 (±0.2) | 0.6 (±0.1) | 0.43 |
| ALP (U/L) | 66.0 (±42.0) | 60.0 (±30.0) | 0.46 |
| Bilirubin (mg/dL) | 0.62 (±0.23) | 0.71 (±0.51) | 0.29 |
| Albumin (g/L) | 41.6 (±3.5) | 41.5 (±2.9) | 0.85 |
| Hemoglobin (g/L) | 146.8 (±10.1) | 147.3 (±9.5) | 0.87 |
| Platelet count (109/L) | 226.1 (±57.0) | 216.5 (±40.7) | 0.49 |
| Prothrombin (INR) | 1.0 (±0.1) | 1.0 (±0.1) | 0.29 |
| Creatinine (mg/dL) | 1.00 (±0.23) | 1.04 (±0.18) | 0.41 |
| Ferritin (µg/L) | 213.6 (±188.7) | 204.1 (±119.4) | 0.83 |
| Fasting glucose (mg/dL) | 108.0 (±36.0) | 109.8 (±43.2) | 0.88 |
| Fibrosis stage (IQR) | 1 (0–2) | 0 (0–1) | 0.17 |
| Steatosis grade (IQR) | 2 (1–3) | 3 (2–3) | 0.29 |
| Lobular inflammation (IQR) | 0 | 0 (0–0.25) | 0.46 |
| Ballooning (IQR) | 0 | 0 | 0.64 |
| NASH (%) | 10.7 (n=6) | 4.5 (n=1) | 0.67 |
Abbreviations: BMI, body mass index; T2DM, type 2 diabetes mellitus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AST/ALT ratio; aspartate aminotransferase/alanine aminotransferase ratio; ALP, alkaline phosphatase; INR, international normalized ratio.